Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia

Neuroscience

Volumn 198, Issue , 2011, Pages 245-251

  Carta, M ^a,b   Bezard, E ^c,d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Dopamine; Dyskinesia; L DOPA; Parkinson's disease; Serotonin

Indexed keywords

AMANTADINE; AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE 1 RECEPTOR; LEVODOPA; SARIZOTAN; SEROTONIN 1A AGONIST; SEROTONIN 1B AGONIST; VESICULAR MONOAMINE TRANSPORTER;

DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DYSKINESIA; EXTRACELLULAR SPACE; HUMAN; NERVE DEGENERATION; NEUROIMAGING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; OXIDOPAMINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; RATS; SEROTONERGIC NEURONS; SEROTONIN;

EID: 81255188854     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.07.070     Document Type: Review

References (63)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Ahmed I., Bose S.K., Pavese N., Ramlackhansingh A., Turkheimer F., Hotton G., Hammers A., Brooks D.J. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011, 134:979-986.
3. Antonini A., Ursino G., Calandrella D., Bernardi L., Plebani M. Continuous dopaminergic delivery in Parkinson's disease. J Neurol 2010, 257:S305-S308.
4. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci Lett 1995, 195:195-198.
5. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res 1994, 667:295-299.
6. Arai R., Karasawa N., Nagatsu I. Aromatic l-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat. A double-labeling immunofluorescence study. Brain Res 1996, 706:177-179.
7. Arai R., Karasawa N., Nagatsu T., Nagatsu I. Exogenous L-5-hydroxytryptophan is decarboxylated in neurons of the substantia nigra pars compacta and locus coeruleus of the rat. Brain Res 1995, 669:145-149.
8. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., Bioulac B.H., Gross C.E., Fisone G., Bloch B., Bezard E. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005, 57:17-26.
9. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., Bloch B. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia. J Neurosci 2009, 15(29):4829-4835.
10. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
11. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
12. Björklund T., Carlsson T., Cederfjäll E.A., Carta M., Kirik D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 2010, 133:496-511.
13. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate l-dopa-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci 2007, 27:8011-8022..
14. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
15. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov Disord 2010, 25(Suppl 1):S174-S179.
16. Cenci M.A., Lindgren H.S. Advanced in understanding l-DOPA-induced dyskinesia. Curr Opin Neurol 2007, 17:665-671.
17. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in l-DOPA-induced dyskinesia. J Neurochem 2006, 99:381-392.
18. Chase T.N., Oh J.D., Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 2000, 247(Suppl 2):II36-II42.
19. Crosby N.J., Deane K.H., Clarke C.E. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev 2003, CD003467.
20. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
21. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
22. Dupre K.B., Eskow K.L., Negron G., Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 2007, 1158:135-143.
23. Dupre K.B., Ostock C.Y., Eslow Jaunarajs K.L., Button T., Savage L.M., Wolf W., Bishop C. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic hemiparkinsonian rats. Exp Neurol 2011, 229:288-299.
24. El Mansari M., Sánchez C., Chouvet G., Renaud B., Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005, 30:1269-1277.
25. Eskow Jaunarajs K.L., Angoa-Perez M., Kuhn D.M., Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment. Neuroscience and Biobehavioral Reviews 2011, 35:556-564.
26. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
27. Everett G.M., Borcherding J.W. l-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 1970, 168:847-850.
28. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., Calabresi P. A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J Neurosci 2006, 15(26):2914-2922.
29. Goetz C.G., Damier P., Hicking C., Laska E., Müller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007, 22:179-186.
30. Guigoni C., Doudnikoff E., Li Q., Bloch B., Bezard E. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 2007, 26:452-463.
31. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
32. Hill M.P., Bezard E., McGuire S.G., Crossman A.R., Grimée R., Brotchie J.M., Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by l-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003, 18:1301-1305.
33. Hollister A.S., Breese G.R., Mueller R.A. Role of monoamine neural systems in l-dihydroxyphenylalanine-stimulated activity. J Pharmacol Exp Ther 1979, 208:37-43.
34. Hsu A., Togasaki D.M., Bezard E., Sokoloff P., Langston J.W., Di Monte D.A., Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 2004, 311:770-777.
35. Kannari K., Tanaka H., Maeda T., Tomiyama M., Suda T., Matsunaga M. Reserpine pretreatment prevents increases in extracellular striatal dopamine following l-DOPA administration in rats with nigrostriatal denervation. J Neurochem 2000, 74:263-269.
36. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 2008, 197:279-293.
37. Lavoie B., Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 1990, 299:1-16.
38. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010, 112:1456-1476.
39. Lopez A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001, 103:639-651.
40. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15:120-132.
41. Meissner W., Ravenscroft P., Reese R., Harnack D., Morgenstern R., Kupsch A., Klitgaard H., Bioulac B., Gross C.E., Bezard E., Boraud T. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 2006, 22:586-598.
42. Mignon L.J., Wolf W.A. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 2005, 16:699-703.
43. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009, 219:298-307.
44. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
45. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010, 38:136-143.
46. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Chronic l-DOPA therapy alters central serotonergic function and l-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis 2011, 41:585-590.
47. Nevalainen N., Af Bjerkén S., Lundblad M., Gerhardt G.A., Strömberg I. Dopamine release from serotonergic nerve fibers is reduced in l-DOPA-induced dyskinesia. J Neurochem 2011, 118:12-23.
48. Ng K.Y., Chase T.N., Colburn R.W., Kopin I.J. l-Dopa-induced release of cerebral monoamines. Science 1970, 170:76-77.
49. Ng K.Y., Colburn R.W., Kopin I.J. Effects of l-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971, 230:331-332.
50. Nutt J.G., Nygaard T.G. Response to levodopa treatment in dopa-responsive dystonia. Arch Neurol 2001, 58:905-910.
51. Nutt J.G., Obeso J.A., Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000, 23:S109-S115.
52. Nygaard T.G., Marsden C.D., Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991, 41:174-181.
53. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat Neurosci 2003, 6:501-506.
54. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010, 68:619-628.
55. Santini E., Sgambato-Faure V., Li Q., Savasta M., Dovero S., Fisone G., Bezard E. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in l-DOPA-induced dyskinesia. PLoS One 2010, 5:e12322.
56. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.A., Hervé D., Greengard P., Fisone G. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J Neurosci 2007, 27:6995-7005.
57. Silverdale M.A., Kobylecki C., Hallett P.J., Li Q., Dunah A.W., Ravenscroft P., Bezard E., Brotchie J.M. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 2010, 64:177-180.
58. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
59. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., Stoessl A.J. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009, 72:1211-1216.
60. Ulusoy A., Sahin G., Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to l-DOPA-induced dyskinesia in rats. Proc Natl Acad Sci U S A 2010, 107:13159-13164.
61. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007, 62:800-810.
62. Zeng B.Y., Iravani M.M., Jackson M.J., Rose S., Parent A., Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol Dis 2010, 40:599-607.
63. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in l-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A 2008, 105:2163-2168.